Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C

Table 3 Serum prohepcidin concentrations in genotype 1 HCV-infected patients during antiviral therapy with respect to SVR (mean ± SE)

	Prohepcidin (ng/mL)		P
	Responders (n = 13)	Non-responders (n = 16)
Baseline	88.8 ± 14.7	88.3 ± 11.4	0.980
6 h	75.2 ± 10.2	79.5 ± 7.2	0.620
24 h	72.6 ± 6.8	68.4 ± 4.6	1.000
48 h	67.9 ± 7.6	64.8 ± 4.3	0.930
7th d	87.9 ± 8.6	85.9 ± 9.6	0.690
4th wk	77.7 ± 9.8	76.0 ± 7.8	0.920
12th wk	71.6 ± 6.7	76.1 ± 5.2	0.350
24th wk	63.9 ± 4.8	82.4 ± 4.3	0.004
48th wk	60.6 ± 2.3	82.3 ± 4.4	< 0.001
ANOVA1	χ2 = 9.6, P = 0.040	χ2 = 2.8, P = 0.590

¹Calculated from data collected at baseline and weeks 4, 12, 24, 48. SVR: Sustained viral response.